Drug intelligence / Profile preview

digoxin

Development stage
Approved
Lead developer
GSK
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous
01

Overview

Digoxin is a cardiac glycoside derived from the leaves of the Digitalis plant. It is primarily used to treat heart failure and certain types of arrhythmias, especially atrial fibrillation and atrial flutter. The drug works by inhibiting sodium-potassium adenosine triphosphatase (Na+/K+ ATPase) in cardiac myocytes. This inhibition increases intracellular sodium levels, which in turn reduces the activity of the sodium-calcium exchanger and leads to increased intracellular calcium concentrations. The elevated calcium enhances myocardial contractility (positive inotropic effect) and slows conduction through the atrioventricular node via increased vagal tone (negative chronotropic effect). These actions help improve cardiac output and control ventricular response rates in arrhythmias[2][3][5][6]. Digoxin also has neurohormonal effects that may benefit patients with heart failure by improving baroreceptor sensitivity and reducing activation of neurohormonal systems[6].

Brand names
DigitekDigoxLanoxinLanoxicapsCardoxin
Other names
digitalis glycoside
02

Targets

ATP1A (Sodium/potassium-transporting ATPase)

Beyond the preview

Go deeper on digoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on digoxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call